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XBP1 is a well-characterized regulator of the unfolding
protein response that is activated in response to
unfolded or misfolded proteins or nutrient deprivation.
The conventional wisdom is that XBP1 is activated
to coordinate the unfolded protein response and
promote cellular survival under stresses. A recent study
provides intriguing evidence that, in triple-negative
breast cancer, XBP1 plays a major role in promoting
oncogenesis and cancer stem cell properties.
Unexpectedly, XBP1 accomplishes this by recruiting
hypoxia-inducible factor 1α and activating oncogenic
transcriptional programs. This study reveals a
surprising hierarchy and alliance between two stress
regulators with distinct transcriptional outputs to
promote an aggressive oncogenic state.many UPR genes [6]. Since the IRE1-XBP1 pathway is
considered an adaptive survival mechanism under stress,Background
Cells within a solid tumor are constantly exposed to fluc-
tuating physical and chemical conditions in the micro-
environment, including pH dysregulation, oxidative stress,
and nutrient deprivation [1]. To cope with these fluctua-
tions, tumor cells demonstrate a wide spectrum of mecha-
nisms that sense and respond to these stresses. For
example, a low partial pressure of oxygen (pO2) level sta-
bilizes the hypoxia-inducible factors (HIFs) and triggers a
hypoxia response [2]. Similarly, various oxidative stresses
promote the nuclear translocation of NRF2 to induce a set
of genes that enhances oxidative-stress tolerance. Al-
though these responses facilitate stress adaptations, many
of these proteins and pathways also play an active role in
promoting or repressing oncogenesis. For example, the* Correspondence: jentsan.chi@duke.edu
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months following its publication. After this time
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org/publicdomain/zero/1.0/) applies to the dataHIFs [3] and NRF2 [4] can be oncogenic and their consti-
tutive activation directly contributes to tumor develop-
ment. Hypoxia pathway is more active in triple-negative
breast cancers (TNBCs) than in other breast cancers [5].
However, the physiologic cause for enhanced HIF-1α pro-
tein levels leading to the elevated hypoxia response re-
mains unknown since these tumors, as a group, do not
have lower pO2 [5].
The IRE1-XBP1 pathway is one of the three branches
of the unfolding protein response (UPR) that senses and
responds to the accumulation of misfolded proteins in
the endoplasmic reticulum (ER) caused by nutrient
deprivation and other stresses. The transmembrane ER
protein IRE1 senses these stresses and excises a 26-bp
segment from the XBP1 mRNA, converting the inactive
unspliced XBP1 to the active spliced XBP1 (XBP1s)
whose translated protein triggers the transcription of
the inhibition of the UPR reduces cellular survival and
tumor growth [7]. Therefore, therapeutic targeting of
IRE1-XBP1 may hamper the UPR required for cancer
cell survival under stress.The article
In a recent letter to Nature, Chen and colleagues [8] pro-
vided intriguing data to show that XBP1 acts as a tumor
driver that is required for oncogenesis and cancer stem
cell phenotypes associated with TNBC. Unexpectedly,
XBP1 mediates its oncogenic properties by physically
interacting with and recruiting HIF-1α to initiate the hyp-
oxia response. The recruitment is essential to induce
oncogenic and self-renewal phenotypes in TNBC. An
XBP1 gene expression signature identified by using ChiP-
seq analysis significantly overlaps with the HIF-1α signa-
ture and is associated with poor prognosis in TNBC. Most
importantly, epistasis analysis indicates that XBP1 lies up-
stream of HIF-1α, occupying the regulatory regions and
recruiting HIF-1α, via direct physical interaction, to the
promoter regions of their shared target genes. Therefore,Ltd. The licensee has exclusive rights to distribute this article, in any medium, for 6
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in TNBC. The authors conclude from these results that
that XBP1s activation and promoter occupancy is not just
a passive adaptive response for survival under stress, but
rather is a driving oncogenic event in TNBC.
The viewpoint
This article provides a potential explanation for the ele-
vated hypoxia pathway activation in TNBC and breast
cancer stem cells. Moreover, although both HIF-1α and
XBP1 are stress-responsive proteins, high baseline activ-
ities of both transcriptional factors can be found in TNBC
without apparent stress exposure. What triggers the IRE1-
XBP1 pathway in TNBC and breast cancer stem cells?
One obvious candidate is hypoxia since it activates both
XBP1 and HIF-1α. However, the pO2 concentration
needed to activate the UPR is much lower (pO2 < 0.01%)
than what is needed to activate HIF-1α [9]. Furthermore,
whereas hypoxia can be readily triggered by low pO2,
XBP1 is activated only by combined low pO2 and lactic
acidosis [10]. Therefore, XBP1 may be activated by com-
bined metabolic stresses associated with the acquisition of
cancer stem cell and TNBC properties. The higher UPR in
TNBC is shown by a dilated ER [8] and increased sensitiv-
ity to hsp90 inhibitors that kill cells by hindering the UPR
[11]. Such a high level of UPR in TNBC may be caused by
increased protein production, higher oxidative stress, or
lower levels of nutrients driven by vigorous glycolysis and
altered glutamine metabolism [12]. Currently, TNBC is
treated primarily by cytotoxic chemotherapies. Targeting
the IRE1-XBP1 pathway, such as with an inhibitor of IRE1
(for example, STF-083010) [13], may have significant
therapeutic value for TNBC.
Of course, these results also raise questions for further
investigation. For example, why does the co-occupancy
of XBP1 and HIF-1α occur in TNBC but not luminal
breast cancer cells? Such differences may be explained
by TNBC-specific chromatin accessibility status or other
available co-activator proteins. Specifically in TNBC,
XBP1 may serve as a ‘pioneer factor’ [14] that recruits
other co-activators to trigger and maintain HIF-1α sta-
bility. A recent study has identified at least seven differ-
ent subtypes of TNBCs with varying sensitivity to hsp90
inhibitors [15]. Therefore, it will be important to deter-
mine the extent of this XBP1-HIF-1α co-regulation
among the subsets of TNBCs as well as cancer stem
cells from other tumor types.
In conclusion, this study shows an unexpected domin-
ant role for XBP1 in the recruitment and activation of
HIF-1α-driven oncogenesis in TNBCs. Like many other
stress response pathways, these proteins are not just pas-
sive players to keep tumors alive under stress. Instead,
stress response proteins can be oncogenic drivers that
coordinate stress tolerance with other transcriptionalfactors to enhance and modulate their expression pro-
grams. Therefore, proteins such as HIF-1α and IRE1-
XBP1 may be excellent targets in our efforts to treat
cancers that have yet to benefit from other targeted
therapeutics.
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